Symvivo Corporation Announces Collaboration with Merck

BURNABY, British Columbia--(BUSINESS WIRE)--Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, announced today that it has entered into a research collaboration with Merck Sharp and Dohme Corp. Under the terms of the agreement, Merck receives an option to take an exclusive license to Symvivo’s bacTRL™ platform technology for use in advancing delivery of oral vaccines.

“We are excited to be collaborating with Merck on this novel program,” said Lloyd Mackenzie, President and Chief Operating Officer at Symvivo. “This agreement builds on Symvivo’s efforts to develop the bacTRL™ platform across a range of diverse and important indications.”

About Symvivo

Symvivo is a clinical-stage biotechnology company advancing a proprietary platform for the site-specific delivery of genes for the treatment and prevention of life-threatening diseases. Symvivo’s bacTRL™ platform technology delivers plasmid DNA, both orally and through IV application, that enables a patient’s own cells to produce therapeutic proteins. Symvivo is advancing therapeutics in the area of oral DNA vaccines, oncology, immunology and protein therapy. Symvivo is headquartered in Burnaby, British Columbia. For more information, visit www.symvivo.com.